Tango Reports 82% Response Rate in Pancreatic Cancer Trial
Key points
- Tango Therapeutics (NASDAQ:TNGX) reported an 82% objective response rate with vopimetostat plus daraxonrasib in previously treated pancreatic cancer patients.
- Median progression-free survival had not been reached, and the nine-month progression-free rate was 88% among 22 evaluable patients.
- Tango plans to start a front-line registrational Phase 3 trial of a daraxonrasib combination in the first half of 2027 and discuss a potential second-line approval pathway with regulators.
Tango Therapeutics (NASDAQ) reported an 82% objective response rate with vopimetostat plus daraxonrasib in previously treated patients with MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma.
At the August 20, 2026 data cutoff, 22 evaluable patients had a median follow-up of 7.1 months, and the nine-month progression-free survival rate was 88%, while median progression-free survival had not been reached.
The supplied announcement summary did not include an executive quote, but Tango reported that seven responses initially unconfirmed at the data cutoff were subsequently confirmed.
At dose level 1, 40% of pancreatic cancer patients experienced Grade 3 treatment-related adverse events, while dose level 2 was not well-tolerated, according to the reported trial findings.
Tango also reported a 54% objective response rate with a zoldonrasib combination among 35 evaluable pancreatic cancer patients, providing a separate set of results for its combination-treatment research.
The company expects to begin a front-line registrational Phase 3 trial of a daraxonrasib combination in the first half of 2027 and plans to discuss a potential second-line approval pathway with regulators.
Tango Therapeutics develops targeted cancer medicines, including treatments designed to exploit specific genetic changes in tumors, with its pancreatic cancer research focused on patients whose tumors have particular molecular characteristics.
